{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:29:41Z","timestamp":1781108981717,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","award":["NCR-18-13804"],"award-info":[{"award-number":["NCR-18-13804"]}],"id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2017SGR00385"],"award-info":[{"award-number":["2017SGR00385"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.biopha.2022.113942","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T08:46:28Z","timestamp":1666946788000},"page":"113942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1017-7216","authenticated-orcid":false,"given":"Emma","family":"Polonio-Alcal\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rut","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ruiz-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"V\u00e1squez-Dongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Relat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bosch-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Ciurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2022.113942_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.biopha.2022.113942_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236580","article-title":"Molecular profiling of non-small cell lung cancer","volume":"15","author":"Forsythe","year":"2020","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.biopha.2022.113942_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2022.113942_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/jmoldx.2008.070178","article-title":"EGFR Mutations in Lung Adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression","volume":"10","author":"Li","year":"2008","journal-title":"J. Mol. Diagn."},{"issue":"4","key":"10.1016\/j.biopha.2022.113942_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: Gefitinib (ZD1839) (Iressa\u00ae) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"issue":"5676","key":"10.1016\/j.biopha.2022.113942_bib6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biopha.2022.113942_bib7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non\u2013small-cell lung cancer to Gefitinib","volume":"352","author":"Kobayashi","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.biopha.2022.113942_bib8","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2022.113942_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.biopha.2022.113942_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.113942_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mce.2017.01.010","article-title":"STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics","volume":"451","author":"Zulkifli","year":"2017","journal-title":"Mol. Cell Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113942_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1158\/0008-5472.CAN-12-2066","article-title":"Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway","volume":"73","author":"Cortot","year":"2013","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","article-title":"EGFR-TKIs resistance via EGFR-independent signaling pathways","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat. Commun."},{"issue":"31","key":"10.1016\/j.biopha.2022.113942_bib16","doi-asserted-by":"crossref","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","article-title":"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1","volume":"109","author":"Ohashi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"75","key":"10.1016\/j.biopha.2022.113942_bib17","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2022.113942_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mam.2013.08.003","article-title":"Lung cancer stem cells: molecular features and therapeutic targets","volume":"39","author":"Singh","year":"2014","journal-title":"Mol. Asp. Med."},{"issue":"4","key":"10.1016\/j.biopha.2022.113942_bib19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.2741\/e478","article-title":"The role of cancer stem cells in relapse of solid tumors","volume":"1","author":"Yu","year":"2012","journal-title":"Front. Biosci."},{"issue":"3","key":"10.1016\/j.biopha.2022.113942_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12013-014-9844-4","article-title":"Lung cancer stem cells and implications for future therapeutics","volume":"69","author":"Wang","year":"2014","journal-title":"Cell Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.biopha.2022.113942_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2022.113942_bib22","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/cbdd.13942","article-title":"Review on target domains and natural compound-based inhibitors of fatty acid synthase for anticancer drug discovery","volume":"98","author":"Pulla","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.biopha.2022.113942_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201708313","article-title":"Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non\u2010small cell lung cancer","volume":"10","author":"Ali","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.113942_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12051283","article-title":"Fatty acid synthase inhibitor G28 shows anticancer activity in EGFR tyrosine kinase inhibitor resistant lung adenocarcinoma models","volume":"12","author":"Polonio-Alcal\u00e1","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2022.113942_bib25","first-page":"4578","article-title":"Inhibition of FASN expression enhances radiosensitivity in human non-small cell lung cancer","volume":"15","author":"Zhan","year":"2018","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.biopha.2022.113942_bib26","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ebiom.2015.06.020","article-title":"Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression","volume":"2","author":"Ventura","year":"2015","journal-title":"EBioMedicine"},{"issue":"34","key":"10.1016\/j.biopha.2022.113942_bib27","doi-asserted-by":"crossref","first-page":"55543","DOI":"10.18632\/oncotarget.10837","article-title":"A FASN-TGF-\u03b21-FASN regulatory loop contributes to high EMT\/ metastatic potential of cisplatin-resistant non-small cell lung cancer","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","article-title":"Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer","volume":"8","author":"Jacobsen","year":"2017","journal-title":"Nat. Commun."},{"issue":"C","key":"10.1016\/j.biopha.2022.113942_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"issue":"5","key":"10.1016\/j.biopha.2022.113942_bib30","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/molecules23051160","article-title":"(\u2212)-Epigallocatechin 3-gallate synthetic analogues inhibit fatty acid synthase and show anticancer activity in triple negative breast cancer","volume":"23","author":"Crous-Mas\u00f3","year":"2018","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.biopha.2022.113942_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11307-012-0587-6","article-title":"Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy","volume":"15","author":"Sankaranarayanapillai","year":"2013","journal-title":"Mol. Imaging Biol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12944-019-1058-8","article-title":"Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT\/ERK pathway","volume":"18","author":"Chang","year":"2019","journal-title":"Lipids Health Dis."},{"issue":"10","key":"10.1016\/j.biopha.2022.113942_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41419-021-04198-2","article-title":"Sulforaphane downregulated fatty acid synthase and inhibited microtubule-mediated mitophagy leading to apoptosis","volume":"12","author":"Yan","year":"2021","journal-title":"Cell Death Dis"},{"issue":"7","key":"10.1016\/j.biopha.2022.113942_bib34","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1158\/0008-5472.CAN-15-0847","article-title":"The ephrin-A1\/EPHA2 signaling axis regulates glutamine metabolism in HER2-positive breast cancer","volume":"76","author":"Youngblood","year":"2016","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2022.113942_bib35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14728222.2022.2077189","article-title":"Fatty acid synthase: a druggable driver of breast cancer brain metastasis","volume":"26","author":"Menendez","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2049-3002-1-3","article-title":"Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth","volume":"1","author":"Griffiths","year":"2013","journal-title":"Cancer Metab"},{"issue":"15","key":"10.1016\/j.biopha.2022.113942_bib37","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/jssc.201801165","article-title":"Preparative isolation and purification of steroidal glycoalkaloid from the ripe berries of Solanum nigrum L. by preparative HPLC\u2013MS and UHPLC\u2013TOF-MS\/MS and its anti-non-small cell lung tumors effects in vitro and in vivo","volume":"42","author":"Shi","year":"2019","journal-title":"J. Sep Sci."},{"issue":"23","key":"10.1016\/j.biopha.2022.113942_bib38","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/1078-0432.CCR-07-1186","article-title":"Selective inhibition of fatty acid synthase for lung cancer treatment","volume":"13","author":"Orita","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.113942_bib39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1471-2407-12-280","article-title":"Different fatty acid metabolism effects of (-)-Epigallocatechin-3-Gallate and C75 in Adenocarcinoma lung cancer","volume":"12","author":"Relat","year":"2012","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.biopha.2022.113942_bib40","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1158\/1078-0432.CCR-15-3133","article-title":"Preclinical evaluation of fatty acid synthase and EGFR inhibition in triple-negative breast cancer","volume":"22","author":"Gir\u00f3-Perafita","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.113942_bib41","doi-asserted-by":"crossref","first-page":"101364","DOI":"10.1016\/j.tranon.2022.101364","article-title":"The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles","volume":"18","author":"Sanaei","year":"2022","journal-title":"Transl. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113942_bib42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1535-7163.MCT-12-0885","article-title":"Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model","volume":"12","author":"Ninomiya","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.biopha.2022.113942_bib43","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1021\/jf204362n","article-title":"(-)-Epigallocatechin gallate induces Fas\/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK\/STAT3 signaling in head and neck squamous cell carcinoma cells","volume":"60","author":"Lin","year":"2012","journal-title":"J. Agric. Food Chem."},{"issue":"2","key":"10.1016\/j.biopha.2022.113942_bib44","doi-asserted-by":"crossref","first-page":"e31067","DOI":"10.1371\/journal.pone.0031067","article-title":"EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer","volume":"7","author":"Tang","year":"2012","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.biopha.2022.113942_bib45","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.7150\/jca.19383","article-title":"Sulforaphane induced apoptosis via promotion of mitochondrial fusion and ERK1\/2-mediated 26S proteasome degradation of novel pro-survival bim and upregulation of bax in human non-small cell lung cancer cells","volume":"8","author":"Geng","year":"2017","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jbior.2013.09.004","article-title":"Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments","volume":"54","author":"Wu","year":"2014","journal-title":"Adv. Biol. Regul."},{"issue":"2","key":"10.1016\/j.biopha.2022.113942_bib47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10637-021-01121-6","article-title":"ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer","volume":"40","author":"Ku","year":"2022","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/jcar.JCar_15_20","article-title":"Lipid metabolism in cancer: a systematic review","volume":"20","author":"Khan","year":"2021","journal-title":"J. Carcinog."},{"issue":"6","key":"10.1016\/j.biopha.2022.113942_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules24061027","article-title":"EGCG-derivative G28 shows high efficacy inhibiting the mammosphere-forming capacity of sensitive and resistant TNBC models","volume":"24","author":"Gir\u00f3-Perafita","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2022.113942_bib50","article-title":"Fatty acid synthase as a feasible biomarker for triple negative breast cancer stem cell subpopulation cultured on electrospun scaffolds","volume":"12","author":"Rabionet","year":"2021","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biopha.2022.113942_bib51","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fphar.2017.00746","article-title":"Mechanistic study of bakuchiol-induced anti-breast cancer stem cell and in vivo anti-metastasis effects","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113942_bib52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12263-015-0499-6","article-title":"Metformin and soybean-derived bioactive molecules attenuate the expansion of stem cell-like epithelial subpopulation and confer apoptotic sensitivity in human colon cancer cells","volume":"10","author":"Montales","year":"2015","journal-title":"Genes Nutr"},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib53","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12935-021-01803-4","article-title":"Modulation of LXR signaling altered the dynamic activity of human colon adenocarcinoma cancer stem cells in vitro","volume":"21","author":"Dianat-Moghadam","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.biopha.2022.113942_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2022.113942_bib55","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening of epidermal growth factor receptor mutation in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2022.113942_bib56","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-07-4177","article-title":"Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors","volume":"14","author":"Orita","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2022.113942_bib57","first-page":"4169","article-title":"Fatty Acid Synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma","volume":"24","author":"Visca","year":"2004","journal-title":"Anticancer Res."},{"issue":"24","key":"10.1016\/j.biopha.2022.113942_bib58","first-page":"271","article-title":"Significance of fatty acid synthase expression in non-small cell lung cancer","volume":"3","author":"Wang","year":"2002","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"6","key":"10.1016\/j.biopha.2022.113942_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.arcmed.2010.08.007","article-title":"Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity","volume":"41","author":"Cerne","year":"2010","journal-title":"Arch. Med. Res."},{"issue":"33","key":"10.1016\/j.biopha.2022.113942_bib60","doi-asserted-by":"crossref","first-page":"34992","DOI":"10.18632\/oncotarget.5252","article-title":"Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation","volume":"6","author":"Bollu","year":"2015","journal-title":"Oncotarget"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222013312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222013312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:13:01Z","timestamp":1778242381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222013312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":60,"alternative-id":["S0753332222013312"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113942","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113942"}}